Knockdown of c-Met enhances sensitivity to bortezomib in human multiple myeloma U266 cells via inhibiting Akt/mTOR activity

APMIS

Volumn 120, Issue 3, 2012, Pages 195-203

  Que, Wenzhong ^a   Chen, Junmin ^a   Chuang, Ma ^a   Jiang, Danrong ^a  

^a FUJIAN MEDICAL UNIVERSITY   (China)

Author keywords

Akt mTOR; Bortezomib; C Met; Multiple myeloma

Indexed keywords

BORTEZOMIB; CASPASE 3; CASPASE 9; CYCLIN D1; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE B; PROTEIN P27; SCATTER FACTOR RECEPTOR;

APOPTOSIS; ARTICLE; CANCER RESISTANCE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVITY; ENZYME INHIBITION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; IC 50; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; BORONIC ACIDS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; HUMANS; INHIBITORY CONCENTRATION 50; MULTIPLE MYELOMA; PROTO-ONCOGENE PROTEINS C-AKT; PYRAZINES; RECEPTOR PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84857112162     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/j.1600-0463.2011.02836.x     Document Type: Article

References (29)

1. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med 2004;351:1860-73.
2. Richardson PG. A review of the proteasome inhibitor bortezomib in multiple myeloma. Expert Opin Pharmacother 2004;5:1321-31.
3. Richardson PG, Mitsiades CS, Hideshima T, Anderson KC. Novel biological therapies for the treatment of multiple myeloma. Best Pract Res Clin Haematol 2005;18:619-34.
4. Harousseau JL. Stem cell transplantation in multiple myeloma. Curr Opin Oncol 2005;17:93-8.
5. Dimopoulos MA, San-Miguel JF, Anderson KC. Emerging therapies for the treatment of relapsed or refractory multiple myeloma. Eur J Haematol 2011;86:1-15.
6. Yang HH, Vescio R, Schenkein D, Berenson JR. A prospective, open-label safety and efficacy study of combination treatment with bortezomib (PS-341, velcade and melphalan in patients with relapsed or refractory multiple myeloma). Clin Lymphoma 2003;4:119-22.
7. Blade J, Cibeira MT, Rosinol L. Bortezomib: a valuable new antineoplastic strategy in multiple myeloma. Acta Oncol 2005;44:440-8.
8. Popat R, Joel S, Oakervee H, Cavenagh J. Bortezomib for multiple myeloma. Expert Opin Pharmacother 2006;7:1337-46.
9. Borset M, Hjorth-Hansen H, Seidel C, Sundan A, Waage A. Hepatocyte growth factor and its receptor c-Met in multiple myeloma. Blood 1996;88:3998-4004.
10. Roccisana J, Reddy V, Vasavada RC, Gonzalez-Pertusa JA, Magnuson MA, Garcia-Ocaña A. Targeted inactivation of hepatocyte growth factor receptor c-met in beta-cells leads to defective insulin secretion and GLUT-2 downregulation without alteration of beta-cell mass. Diabetes 2005;54:2090-102.
11. Giordano S, Ponzetto C, DiRenzo MF, Cooper CS, Comoglio PM. Tyrosine kinase receptor indistinguish able from the c-Met protein. Nature 1989;339:155-6.
12. Borset M, Lien E, Espevik T, Helseth E, Waage A, Sundan A. Concomitant expression of hepatocyte growth factor/scatter factor and the receptor c-MET in human myeloma cell lines. J Biol Chem 1996;271:24655-61.
13. Derksen PW, De-Gorter DJ, Meijer HP, Bende RJ, Van DM, Lokhorst HM, et al. The hepatocyte growth factor/Met pathway controls proliferation and apoptosis in multiple myeloma. Leukemia 2003;17:764-74.
14. Holt RU, Baykov V, Ro TB, Brabrand S, Waage A, Sundan A, et al. Human myeloma cells adhere to fibronectin in response to hepatocyte growth factor. Haematologica 2005;90:479-88.
15. Hov H, Holt RU, Ro TB, Fagerli UM, Hjorth-Hansen H, Baykov V, et al. A selective c-Met inhibitor blocks an autocrine hepatocyte growth factor growth loop in ANBL-6 cells and prevents migration and adhesion of myeloma cells. Clin Cancer Res 2004;10:6686-94.
16. Du W, Hattori Y, Yamada T, Matsumoto K, Nakamura T, Sagawa M, et al. NK4, anantagonist of hepatocyte growth factor (HGF), inhibits growth of multiple myeloma cells: molecular targeting of angiogenic growth factor. Blood 2007;109:3042-9.
17. Morgensztern D, Mcleod HL. PI3K/Akt/mTOR pathway as a target for cancer therapy. Anticancer Drugs 2005;16:797-803.
18. Li Y, Guessous F, DiPierro C, Zhang Y, Mudrick T, Fuller L, et al. Interactions between PTEN and the c-Met pathway in glioblastoma and implications for therapy. Mol Cancer Ther 2009;8:376-85.
19. Whittaker S, Marais R, Zhu AX. The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene 2010;29:4989-5005.
20. Holt RU, Fagerli UM, Baykov V, Rø TB, Hov H, Waage A, et al. Hepatocyte growth factor promotes migration of human myeloma cells. Haematologica 2008;93:619-22.
21. Que WZ, Chen JM. Knockdown of c-Met inhibits cell proliferation and invasion and increases chemosensitivity to doxorubicin in human multiple myeloma U266 cells in vitro. Mol Med Rep 2011;4:343-9.
22. Cañadas I, Rojo F, Arumí-Uría M, Rovira A, Albanell J, Arriola E. C-MET as a new therapeutic target for the development of novel anticancer drugs. Clin Transl Oncol 2010;12:253-60.
23. Iwasaki T, Hamano T, Ogata A, Hashimoto N, Kitano M, Kakishita E. Clinical significance of vascular endothelial growth factor and hepatocyte growth factor in multiple myeloma. Br J Haematol 2002;116:796-802.
24. Teru H, Constantine M, Masaharu A, Hayashi T, Chauhan D, Richardson P, et al. Molecular mechanism mediating antimyeloma activity of proteasome inhibitor PS-341. Blood 2003;101:1530-4.
25. McMillin DW, Ooi M, Delmore J, Negri J, Hayden P, Mitsiades N, et al. Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235. Cancer Res 2009;69:5835-42.
26. Takuwa N, Fukui Y, Takuwa Y. Cyclin D1 expression mediated by phosphatidylinositol 3-kinase through mTOR-p70 (S6K)-independent signaling in growth factor-stimulated NIH 3T3 fibroblasts. Mol Cell Biol 1999;19:1346-58.
27. Shin I, Yakes FM, Rojo F, Shin NY, Bakin AV, Baselga J, et al. PKB/Akt mediates cell-cycle progression by phosphorylation of p27 (kip1) at threonine 157 and modulation of its cellular localization. Nat Med 2002;8:1145-52.
28. Fiano V, Ghimenti C, Imarisio S, Silengo L, Schiffer D. Pakt, cyclin D1 and p27/kip1 in glioblastomas with and without EGFR amplification and PTEN mutaion. Anticancer Res 2004;24:2643-7.
29. Allan LA, Clarke PR. Apoptosis and autophagy: regulation of caspase-9 by phosphorylation. FEBS J 2009;276:6063-73.